TAKEDA PHARMACEUTICAL CO LTD
TAKDrugs in Pipeline
58
Phase 3 Programs
45
Upcoming Catalysts
1
Next Catalyst
Aug 20, 2026
27wMarket Overview
Stock performance and market intelligence
1 upcoming, 0 past
TAK-360 Phase 2 Results Expected
Primary completion for TAK-360 trial (NCT06952699) in Narcolepsy Type 2
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Apremilast
Plaque Psoriasis
Alogliptin and pioglitazone
Type 2 Diabetes Mellitus
Vedolizumab
Colitis, Ulcerative
TAK-861
Narcolepsy Type 1
Azilsartan medoxomil and chlorthalidone
Essential Hypertension
Vortioxetine
Major Depressive Disorder
TAK-881
Primary Immunodeficiency Diseases (PID)
TAK-536
Hypertension
Lapaquistat Acetate
Dyslipidemia
Pioglitazone
Diabetes Mellitus
TAK-875
Diabetes Mellitus
Maribavir
Cytomegalovirus (CMV)
Tetravalent Dengue Vaccine (TDV)
Dengue Fever
Glimepiride
Diabetes Mellitus
Ramelteon
Sleep Initiation and Maintenance Disorders
TDV
Dengue Fever
Dexlansoprazole MR
Gastroesophageal Reflux Disease
Ixazomib
Multiple Myeloma
SYR-472
Diabetes Mellitus
Pantoprazole
Gastroesophageal Reflux Disease (GERD)
Mezagitamab
Immune Thrombocytopenic Purpura (ITP)
Relugolix
Uterine Fibroids
Febuxostat
Gout
Allopurinol
Gout
Rapid-acting insulin secretagogue
Diabetes Mellitus
Candesartan
Heart Failure
Alogliptin and glimepiride
Type 2 Diabetes Mellitus
Alogliptin
Diabetes Mellitus, Type 2
Azilsartan medoxomil
Essential Hypertension
Zasocitinib
Psoriatic Arthritis
TAK-438
Gastric Ulcers
Soticlestat
Dravet Syndrome (DS)
Lansoprazole
Esophagitis, Reflux
Vedolizumab IV
Moderately to Severely Active Ulcerative Colitis
TAK-279
Plaque Psoriasis
Vonoprazan
Gastroesophageal Reflux
Elritercept
Myelodysplastic Syndromes
Dexlansoprazole
Gastroesophageal Reflux Disease
Vedolizumab SC
Ulcerative Colitis
Lubiprostone
Constipation
TAK-755
Thrombotic Thrombocytopenic Purpura (TTP)
Azilsartan
Hypertension
Metformin
Type 2 Diabetes Mellitus
Duloxetine
Major Depressive Disorder
Fazirsiran Injection
Alpha1-Antitrypsin Deficiency
TAK-954
Postoperative Gastrointestinal Dysfunction
TAK-079
Primary Immune Thrombocytopenia
TAK-019
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
TAK-063 20 mg
Schizophrenia
MCC-135
Congestive Heart Failure
Sitagliptin
Diabetes Mellitus
Brentuximab Vedotin
Lymphoma
Ponatinib
Myeloid Leukemia, Chronic, Chronic Phase
Lapaquistat acetate and atorvastatin
Hypercholesterolemia
NoV GI.1/GII.4 Bivalent VLP Vaccine
Norovirus
Candesartan cilexetil
Essential Hypertension
Peginesatide
Anemia
Cabozantinib
Advanced Renal Cell Carcinoma
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Apremilast | Phase 3 | Plaque Psoriasis | - |
Alogliptin and pioglitazone | Phase 3 | Type 2 Diabetes Mellitus | - |
Vedolizumab | Phase 3 | Colitis, Ulcerative | - |
TAK-861 | Phase 3 | Narcolepsy Type 1 | - |
Azilsartan medoxomil and chlorthalidone | Phase 3 | Essential Hypertension | - |
Vortioxetine | Phase 3 | Major Depressive Disorder | - |
TAK-881 | Phase 3 | Primary Immunodeficiency Diseases (PID) | - |
TAK-536 | Phase 3 | Hypertension | - |
Lapaquistat Acetate | Phase 3 | Dyslipidemia | - |
Pioglitazone | Phase 3 | Diabetes Mellitus | - |
TAK-875 | Phase 3 | Diabetes Mellitus | - |
Maribavir | Phase 3 | Cytomegalovirus (CMV) | - |
Tetravalent Dengue Vaccine (TDV) | Phase 3 | Dengue Fever | - |
Glimepiride | Phase 3 | Diabetes Mellitus | - |
Ramelteon | Phase 3 | Sleep Initiation and Maintenance Disorders | - |
TDV | Phase 3 | Dengue Fever | - |
Dexlansoprazole MR | Phase 3 | Gastroesophageal Reflux Disease | - |
Ixazomib | Phase 3 | Multiple Myeloma | - |
SYR-472 | Phase 3 | Diabetes Mellitus | - |
Pantoprazole | Phase 3 | Gastroesophageal Reflux Disease (GERD) | - |
Mezagitamab | Phase 3 | Immune Thrombocytopenic Purpura (ITP) | - |
Relugolix | Phase 3 | Uterine Fibroids | - |
Febuxostat | Phase 3 | Gout | - |
Allopurinol | Phase 3 | Gout | - |
Rapid-acting insulin secretagogue | Phase 3 | Diabetes Mellitus | - |
Candesartan | Phase 3 | Heart Failure | - |
Alogliptin and glimepiride | Phase 3 | Type 2 Diabetes Mellitus | - |
Alogliptin | Phase 3 | Diabetes Mellitus, Type 2 | - |
Azilsartan medoxomil | Phase 3 | Essential Hypertension | - |
Zasocitinib | Phase 3 | Psoriatic Arthritis | - |
TAK-438 | Phase 3 | Gastric Ulcers | - |
Soticlestat | Phase 3 | Dravet Syndrome (DS) | - |
Lansoprazole | Phase 3 | Esophagitis, Reflux | - |
Vedolizumab IV | Phase 3 | Moderately to Severely Active Ulcerative Colitis | - |
TAK-279 | Phase 3 | Plaque Psoriasis | - |
Vonoprazan | Phase 3 | Gastroesophageal Reflux | - |
Elritercept | Phase 3 | Myelodysplastic Syndromes | - |
Dexlansoprazole | Phase 3 | Gastroesophageal Reflux Disease | - |
Vedolizumab SC | Phase 3 | Ulcerative Colitis | - |
Lubiprostone | Phase 3 | Constipation | - |
TAK-755 | Phase 3 | Thrombotic Thrombocytopenic Purpura (TTP) | - |
Azilsartan | Phase 3 | Hypertension | - |
Metformin | Phase 3 | Type 2 Diabetes Mellitus | - |
Duloxetine | Phase 3 | Major Depressive Disorder | - |
Fazirsiran Injection | Phase 3 | Alpha1-Antitrypsin Deficiency | - |
TAK-954 | Phase 2 | Postoperative Gastrointestinal Dysfunction | - |
TAK-079 | Phase 2 | Primary Immune Thrombocytopenia | - |
TAK-019 | Phase 2 | Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) | - |
TAK-063 20 mg | Phase 2 | Schizophrenia | - |
MCC-135 | Phase 2 | Congestive Heart Failure | - |
Sitagliptin | Phase 2 | Diabetes Mellitus | - |
Brentuximab Vedotin | Phase 2 | Lymphoma | - |
Ponatinib | Phase 2 | Myeloid Leukemia, Chronic, Chronic Phase | - |
Lapaquistat acetate and atorvastatin | Phase 2 | Hypercholesterolemia | - |
NoV GI.1/GII.4 Bivalent VLP Vaccine | Phase 2 | Norovirus | - |
Candesartan cilexetil | Phase 2 | Essential Hypertension | - |
Peginesatide | Phase 2 | Anemia | - |
Cabozantinib | Phase 2 | Advanced Renal Cell Carcinoma | - |
Regulatory & News
Approvals, filings, and latest developments